Joel M. Topf, MD FACP

Saying the product of the kidneys is urine is like saying the product of a factory is pollution. Urine is a by-product. The product is homeostasis
COI: link👇🏼

[Joel M. Topf, MD FACP @kidney_boy]

Didn’t match in Cards?
Crit Care froze you out?
Is that hospitalist job looking too intellectually bankrupt?

Don’t get mad. Choose nephrology!

We have a spot in the July 2026 class that would fulfill dreams you didn’t know you had!

Slip into my DMs

[Joel M. Topf, MD FACP @kidney_boy]

Fellow graduation. Two of the best fellows we have ever graduated

Ram Palepu and Michael Peniston

[Michael Weintraub, MD @MWeintraubMD]

The American Diabetes Association chair elect and conference chair resigned, in the latest update.

https://t.co/VMCSLO3Pob

[Kenar Jhaveri @kdjhaveri]

ASN Kidney News June 2026 Finally, an RCT in Hyponatremia Management: A “HIT” or a Miss?
Samiddhi Weerasiri @Nephro_Sparks
https://t.co/PqjCSksrxe @asnpublications

[Andrea Angioi, MD, FASN @andreaangioi]

We assume targeting B cells means depleting as many as possible.

IgAN says otherwise. Rituximab wipes out circulating CD20+ → no effect. Blocking APRIL/BAFF hits the right cell → eGFR slope ≈ physiologic decline.

It wasn’t depth. It was aim.

https://t.co/m9ajR7ozyC

#IgAN #Nephrology #KDIGO

[Joel M. Topf, MD FACP @kidney_boy]

New @FreelyFiltered Live from Dublin, it's the Irish Nephrology Society!

https://t.co/XC34044Iq7

[Joel M. Topf, MD FACP @kidney_boy]

Ken, in August 1998 RotaShield rota virus vaccine was approved and incorporated into the routine vaccine schedule. Doctors noticed an increase in intussusception after the vaccination and within a year the vaccine was no longer recommended and by October 1999 the drug was pulled from the market.

Doctors and this "organized group" did not stand in the way for criticism of a vaccine that caused actual harm (it was rare, about 100 cases vs an estimated 1.5 million administrations of RotaShield)

[Dr. Alice Cheng @AliceYYCheng]

As the speaker stated today … “my most important slide”. #ADA2026.

[Harold Szerlip, MD @Pissprophet]

@kidney_boy All physicians and scientists need to stand up for truth. The present administration is gutting research, and disregarding science. We cannot let this happen.

[Joel M. Topf, MD FACP @kidney_boy]

Police Tussle With Diabetes Experts at ADA Meeting https://t.co/LnOsJSMb0J

[JAMA @JAMA_current]

🧵 Presented today at #ERA26:

Among adults with chronic #kidney #disease (#CKD) due to glomerular diseases, finerenone slowed eGFR decline, reduced albuminuria, and lowered risk of kidney failure, with consistent benefits across disease subtypes and in those using #SGLT2 inhibitors.

https://t.co/zWGXBXf13K

[Brian Rifkin, MD @brian_rifkin]

#NephJC made it into #ERA26 👏
@CristinaDeReins

https://t.co/7PF0ocJfbj

[Joel M. Topf, MD FACP @kidney_boy]

ASN 2026 Awards
ASN President's Medal
• William E. Flanary, MD

John P. Peters Award
• Adeera Levin, MD, FRCPC, FACP

Homer W. Smith Award
• Matthias Kretzler, MD

Donald W. Seldin Young Investigator
• Jordana B. Cohen, MD, MS, FASN

Robert G. Narins Award
• Ravindra L. Mehta, MD, MBBS, DM, FASN

Belding H. Scribner Award
• Tom Greene, PhD

Barbara T. Murphy Award
• Sharon M. Moe, MD, FASN

[Brian Rifkin, MD @brian_rifkin]

Ready for LBCT 2 🔥 #ERA26

[Joel M. Topf, MD FACP @kidney_boy]

Otsuka kidney drug [Ed: Sibe] slowed loss of function, but less than expected, in late-stage trial https://t.co/7Ld4v27d2d via @statnews

[Tiffany Caza @Tiff_Caza]

@kidney_boy It's catchy though, kinda makes me want to go learn about hyponatremia. Somehow you, @NephRodby, and the @BookBurton team has made it fascinating (even to non-nephs like me!)

[Tiffany Caza @Tiff_Caza]

@NephRodby @kidney_boy @BookBurton @arkanalabs Thanks, but I 💚 working at @arkanalabs! We can be nephro-philes without being nephrologists 🙃

[Wisit Cheungpasitporn MD FACP | FASN | FAST @wisit661]

😃🙏🏻 Honored to meet Professor Jürgen Floege, Editor-in-Chief of Clinical Kidney Journal (CKJ), in person at ERA 2026, in Glasgow, UK @CKJsocial @ERAkidney

It was inspiring to hear his overview of CKJ’s impressive achievements over the past year and its exciting future direction. Under his leadership, CKJ continues to reach new heights in scientific quality, global influence, and academic impact, becoming one of the leading journals in nephrology. We are proud to support CKJ through peer review and scientific collaboration, helping advance kidney research, education, and patient care worldwide.
@PepaSolerR @HerrmannMd @MayoClinicNeph

[Joel M. Topf, MD FACP @kidney_boy]

New episode of The Burton Rose Book Club, Chapter 20, Respiratory Acidosis

https://t.co/91YCf6cwjl

[Joel M. Topf, MD FACP @kidney_boy]

@rmohty @GrahamAbra

[Joel M. Topf, MD FACP @kidney_boy]

ASN has released the program this year's #KidneyWk and I always thought they should lean into controversy, but this is going over the line.
A cage match?
Bare knuckle boxing?

[Joel M. Topf, MD FACP @kidney_boy]

https://t.co/ZYuj3Bvdzq